Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Jounce Therapeutics, Inc. (JNCE) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/10/2022 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2022 Financial Results - INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress -"
08/04/2022 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Second Quarter 2022 Financial Results - INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end -"
05/05/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2021 Financial Results - Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 -"
08/05/2021 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Second Quarter 2021 Financial Results - INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-"
02/25/2021 8-K Quarterly results
11/06/2020 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2020 Financial Results -On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811-"
08/07/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2019 Financial Results - New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash burn guidance reduced - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., November 7, 2019 - Jounce Therapeutics, Inc. , a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate update. “We have continued to work diligently on advancing our pipeline and further executing on our clinical development plans through our Translational Sc..."
08/07/2019 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Second Quarter 2019 Financial Results - Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with Celgene, received $50.0 million upfront - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., August 7, 2019 - Jounce Therapeutics, Inc. , a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today reported financial results for the second quarter ended June 30, 2019 and provided a corporate update. “2019 has been a time of clinical progress and important strategic business development activity for Jounce, with the in..."
05/08/2019 8-K Quarterly results
Docs: "Jounce Therapeutics Reports First Quarter 2019 Financial Results - New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., May 8, 2019 - Jounce Therapeutics, Inc. , a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today reported financial results and provided a corporate update for the first quarter ended March 31, 2019. “We have made significant progress in recent months by applying our Translational Science Platform and reverse translational approach to a..."
03/06/2019 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results - New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab , with ipilimumab and with pembrolizumab - - Ended 2018 with $195.9 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., March 6, 2019 - Jounce Therapeutics, Inc. , a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today reported financial results and provided a corporate update for the fourth quarter and year ended December 31, 2018. “2018 was an important..."
11/13/2018 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2018 Financial Results - Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track - - IND filed and clearance to proceed received for JTX-4014 PD-1 program - - On track for IND filing for JTX-8064, first tumor-associated macrophage program - - Ended third quarter 2018 with $214.7 million in cash - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., November 13, 2018 - Jounce Therapeutics, Inc. , a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results and provided a corporate update for the third quarter ended September 30, 2018. “We a..."
08/09/2018 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Second Quarter 2018 Financial Results - Initiated enrollment in dose escalation cohorts of Phase 1/2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab - - Presented preliminary efficacy data for JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting - - Ended the second quarter with $232.7 million in cash - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., August 9, 2018 - Jounce Therapeutics, Inc. , a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results and provided a corporate update for the second quarter ended June 30, 2018. “We recently reported safety and p..."
05/09/2018 8-K Quarterly results
Docs: "Jounce Therapeutics Reports First Quarter 2018 Financial Results - Preliminary efficacy data from Phase 1/2 ICONIC trial to be presented as an oral presentation at the 2018 ASCO Annual Meeting - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., May 9, 2018 - Jounce Therapeutics, Inc. , a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results and provided a corporate update for the quarter ended March 31, 2018. “The first quarter of 2018 has marked a time of consistent progress for our JTX-2011 clinical program and preclinical pipeline,” said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. “We remain focused on our key ..."
03/08/2018 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC trial in the second quarter of 2018 - - Reiterate 2018 strategy to advance clinical and research pipeline to drive long-term value - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., March 8, 2018 - Jounce Therapeutics, Inc. , a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today reported financial results and provided a corporate update for the quarter and year ended December 31, 2017. “2017 was an important year of execution for Jounce, and our first year as a publicly-traded company. Our corpora..."
11/13/2017 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2017 Financial Results - Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointments - - Update full year financial guidance - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., November 13, 2017 - Jounce Therapeutics, Inc. , a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today reported financial results and provided a corporate update for the quarter ended September 30, 2017. “During the third quarter, Jounce continued to progress on the ongoing Phase 2 portion of the ICONIC study. We are pleased with the ICONIC ..."
08/09/2017 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Second Quarter 2017 Financial Results - Presented Phase 1 data from ICONIC study of JTX-2011 at the 2017 American Society of Clinical Oncology Annual Meeting - - Initiated Phase 2 portion of ICONIC study evaluating JTX-2011 in advanced solid tumors in both monotherapy and combination settings - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., August 9, 2017 - Jounce Therapeutics, Inc. , a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled with predictive biomarkers for patient enrichment, today reported financial results and provided a corporate update for the second quarter ended June 30, 2017. “The second quarter was marked by significant progress as we reported our first..."
05/09/2017 8-K Form 8-K - Current report
03/10/2017 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy